Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients

Renal Failure

Volumn 27, Issue 2, 2005, Pages 177-182

  Hassan, Kamal ^a   Roguin, Nathan ^a   Kaganov, Yan ^a   Hasan, Shadi ^b   Kristal, Batya ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Deformability; Filterability; Predialysis; Rheology; Ventricular mass

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; DOXAZOSIN; ERYTHROPOIETIN; FIBRINOGEN; FUROSEMIDE; HEMOGLOBIN; METOPROLOL FUMARATE;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSIS; ERYTHROCYTE FILTERABILITY; EVALUATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; MORTALITY; PRIORITY JOURNAL; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TIME; VISCOELASTICITY;

AGED; ANEMIA; ECHOCARDIOGRAPHY, THREE-DIMENSIONAL; ERYTHROCYTE DEFORMABILITY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 15344347482     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200048227     Document Type: Article

References (41)

1. Raine, A.E.G.; Margreiter, R.; Brunner, F.P.; Ehrich, J.H.; Geerlings, W.; Landais, P.; Loirat, C.; Mallick, N.P.; Selwood, N.H.; Tufveson, G. Report on management of renal failure in Europe, XXII, 1991. Nephrol. Dial. Transplant. 1992, 7 (suppl. 2), 7-35.
2. Levin, A.; Singer, J.; Thompson, C.R.; Ross, H.; Lewis, M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am. J. Kidney Dis. 1996, 27, 347-354.
3. Amann, K.; Rychlik, I.; Miltenberger-Milteny, G.; Ritz, E. Left ventricular hypertrophy in renal failure. Kidney Int. 1998, S78-S85.
4. Parfrey, P.S.; Harnett, J.D. Clinical aspects of cardiomyopathy in dialysis patients. Blood Purif. 1994, 12, 267-276.
5. Silberberg, J.S.; Rahal, D.P.; Patton, D.R.; Sniderman, A.D. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am. J. Cardiol. 1989, 64, 222-224.
6. London, G.M.; Fabiani, F.; Marchais, S.J.; de Vernejoul, M.C.; Guerin, A.P.; Safar, M.E.; Metivier, F.; Llach, F. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987, 31, 973-980.
7. Silberberg, J.S.; Rahal, D.P.; Patton, R.; Sniderman, A.D. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am. J. Cardiol. 1989, 64, 222-224.
8. Lawrence, N.S.; Braunwald, E.; Rosenthal, D.S. Hematological-oncological disorders and heart disease. In Heart Disease: A Textbook of Cardiovascular Medicine, 5th Ed.; Braunwald, E., Ed.; Saunders: Philadelphia, 1997.
9. Shasha, S.M.; Kamal, H.; Kristal, B.; Galetzky, G.; Roguin, N.; Shkolnik, T. Red cell filterability in cigarette smokers and its relations to cardiac hypertrophy. Atherosclerosis 1993, 98, 91-98.
10. Devereux, R.B.; Drayer, J.M.; Chien, S. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am. J. Cardiol. 1984, 54, 592-595.
11. Wizemann, V.; Schafer, R.; Kramer, W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993, 64, 202-206.
12. Portoles, J.; Torralbo, A.; Martin, P.; Rodrigo, J.; Herrero, J.; Barrientos, A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am. J. Kidney Dis. 1997, 29, 541-548.
13. Macdougall, I.C.; Davies, M.E.; Hutton, R.D.; Coles, G.A.; Williams, G.D. Rheological studies during treatment of renal anemia with recombinant human erythropoietin. Br. J. Haematol. 1991, 77, 550-558.
14. Fellner, S.K.; Lang, R.M.; Neumann, A.; Korsarz, C.; Borow, K.M. Cardiovascular consequenses of correction of the anemia of renal failure with erythropoietin. Kidney Int. 1993, 44, 1309-1315.
15. Raine, A.E. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988, 16, 97-100.
16. Brown, C.D.; Friedman, E.A. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients. Am. J. Nephrol. 1990, 29-33.
17. Shand, B.I.; Buttimore, A.L.; Lynn, K.L.; Bailey, R.R.; Robson, R.A. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity. Ren. Fail. 1994, 16, 407-413.
18. Paulitschke, M.; Ludat, K.; Riedel, E.; Hampl, H. Long effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits. Clin. Nephrol. 2000, 53, 36-41.
19. Bohler, T.; Leo, A.; Linderkamp, O.; Braun, A.; Scharer, K. Hemorheological changes in uraemic children in response to erythropoietin treatment. Nephrol. Dial. Transplant. 1993, 8, 140-145.
20. Teitel, P. Basic principles of the filtrability test and analysis of erythrocytes flow behavior. Blood Cells 1977, 3, 55-59.
21. Devereux, R.B.; Alonso, D.R.; Lutas, E.M.; Gottlieb, G.J.; Campo, E.; Sachs, I.; Reichek, N. Electrocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986, 57, 450-458.
22. Albertazzi, A.; Di Liberato, L.; Daniele, F.; Battistel, V.; Colombi, L. Efficacy and tolerability of recombinant human erythropoietin treatment in predialysis patients: results of multicenter study. Int. J. Artif. Organs 1988, 21, 12-18.
23. Rossert, J.; McClellan, W.; Roger, S.D.; Verbeelen, D.L. Epoetin treatment: what are the argument to expect a beneficial effect on renal disease progression? Nephrol. Dial. Transplant. 2002, 17, 359-362.
24. Typolyai, M.; Kadomatsu, S.; Perera-Chong, M. r.hu-erythropoietin (EPO) treatment of pre-dialysis patients slows the rate of progression of renal decline. BMC Nephrol. 2003, 4 (1), 3.
25. Rossert, J.; Fouqueray, B.; Boffa, J.J. Anemia management and the delay of chronic renal failure progression. J. Am. Soc. Nephrol. 2003, 14 (7 suppl. 2), S173-S177.
26. Silverberg, D.; Wexler, D.; Blum, M.; Wollman, Y.; Iaina, A. The cardio-renal anaemia syndrome: does it exist? Nephrol. Dial. Transplant. 2003, 18 (suppl. 8), viii7-viii12.
27. Dimkovic, N. Erythropoietin administration in the predialysis period. Med. Pregl. 2003, 56 (11-12), 529-535.
28. Crepaldi, G.; Calabro, A.; Belloni, M.; Ongaro, G.; Muggeo, M. Blood hyperviscosity syndromes. Ric. Clin. Lab. 1983, 13 (suppl. 3), 89-104.
29. Linde, T.; Sandhagen, B.; Wikstorm, B.; Danielson, B.G. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability. Nephrol. Dial. Transplant. 1997, 12, 2375-2379.
30. Mohandas, N.; Chasis, J.A. Red blood cell deformability, membrane material properties and shape: regulation by transmemrane, skeletal and cytosolic proteins and lipids. Semin. Hematol. 1993, 30, 171-192.
31. Mohandas, N.; Evans, E. Mechanical properties of the red cell membrane in relation to molecular structure and genetic defects. Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 787-818.
32. Delamaire, M.; Durand, F.; Hamel, D.; Joyeux, V.; Lepogamp, P.; Genetet, B. Improvement of hemorheologic parameters in hemodialyzed patients treated with human recombinant erythropoietin. J. Mal. Vasc. 1991, 16, 289-294.
33. Schmidt, R.; Lerche, D.; Dorp, E.; Winkler, R.; Klinkmann, H. Changes in rheology and red cell function under recombinant human erythropoietin therapy. Pol. Arch. Med. Wew. 1991, 85, 384-390.
34. Icardi, A.; Paoletti, E.; Traverso, G.B.; Sarchi, C.; Cappelli, G.; Molinelli, G. Red cell membrane during erythropoietin therapy in hemodialysis and hemodifiltration. Int. J. Artif. Organs 1991, 14, 147-149.
35. Meier, W.; Paulitschke, M.; Lerche, D.; Schmidt, G.; Zoellner, K. Action of rHuEpo on mechanical membrane properties of red blood cells in children with end-stage renal disease. Nephrol. Dial. Transplant. 1991, 6, 110-116.
36. Foly, R.N.; Parfrey, P.S.; Sarnak, M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998, 32 (suppl. 3), S112-S119.
37. USRDS: annual data report VI. Causes of death. Am. J. Kidney Dis. 1998, 32 (suppl. 1), S81-S88.
38. Varat, M.A.; Adolph, R.J.; Fowler, N.O. Cardiovascular effects of anemia. Am. Heart J. 1972, 83, 415-426.
39. London, G.; Parfrey, P.S. Cardiac disease in chronic uremia: pathogenesis. Adv. Renal Replace. Ther. 1997, 4, 194-211.
40. Metivier, F.; Marchais, S.J.; Guerin, A.P.; Pannier, B.; London, G.M. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol. Dial. Transplant. 2000, 15 (suppl. 3), 14-18.
41. Juul, S.E.; Yachnis, A.T.; Christensen, R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the devolping human fetus. Early Hum. Dev. 1998, 52, 235-249.